The scale of the problem the guidelines are meant to address is staggering. Osteoporosis, a disorder in which low bone mass and deteriorating bone microarchitecture render skeletons dangerously fragile, currently affects roughly one in three women and one in five men over the age of 50 worldwide. A 2022 meta-analysis put global prevalence at 19.7 percent, with significantly higher rates in low- and middle-income countries. In China, a recent systematic review estimated that 13.5 percent of adults aged 20 to 89 had the disease under World Health Organization diagnostic criteria as of 2020. Because the condition is silent until a bone breaks, it is chronically underdiagnosed: approximately half of women and a fifth of men over 50 are expected to sustain an osteoporosis-related fracture, and by 2050 half of all hip fractures on Earth are projected to occur in Asia, with China bearing a disproportionate share of the burden.

The financial stakes are equally stark. Annual costs of osteoporosis-related fractures in China are projected to reach 25.43 billion US dollars by 2050 and to keep climbing as the population ages. Yet unlike the United Kingdom’s Royal College of Physicians or the United States’ Bone Health and Osteoporosis Foundation, which each issued a single authoritative national guideline, China has no universally recognised standard. The first mainland Chinese guideline appeared in 2006, but since then dozens of professional societies spanning orthopaedics, endocrinology, geriatrics, rehabilitation medicine, radiology, general practice, and traditional Chinese medicine have produced their own documents, each reflecting a different disciplinary perspective.

To map this landscape, researchers led by Ting Wei of Western Sydney University systematically searched English-language databases including Medline, Embase, the Cochrane Library, and Web of Science, alongside Chinese databases such as the China National Knowledge Infrastructure and Wanfang, and the websites of Chinese government bodies including the National Health Commission. From 8,100 records published up to 13 August 2026, independent reviewers screened titles, abstracts, and full texts, ultimately including 32 guidelines produced by more than 60 professional societies. Twenty-nine originated in mainland China, two in Hong Kong, and one in Taiwan, and 18 of the 32 appeared between 2022 and 2026, reflecting an accelerating output of guidance documents. Each guideline was appraised with the AGREE II instrument, the international standard for evaluating the methodological quality of clinical guidance.

The review found genuine consensus on fundamentals. All guidelines that addressed diagnosis endorsed dual-energy X-ray absorptiometry, or DXA, as the diagnostic tool of choice for measuring bone mineral density, and the guidelines broadly agreed on the definition of osteoporosis, its diagnostic criteria, and core prevention strategies such as calcium and vitamin D supplementation, exercise, dietary modification, and smoking cessation. Pharmacological and non-pharmacological approaches featured across the board: calcium and vitamin D appeared in 94 percent of guidelines, physical exercise in 91 percent, and patient education in 63 percent. Traditional Chinese medicine, aimed at tonifying the kidney and yang, strengthening the spleen and bones, and promoting circulation, was recommended in two-thirds of all guidelines, a distinctive feature of the Chinese context that has no equivalent in Western guidance.

Beneath this surface agreement, however, lay significant discordance. Bisphosphonates, the workhorse antiresorptive drugs, were recommended in every guideline addressing pharmacological therapy, yet only six explicitly identified them as first-line treatment, whereas US and UK guidelines are unambiguous on this point. Newer agents showed a striking temporal gradient: denosumab was recommended in all guidelines published from 2022 onwards, while romosozumab, a sclerostin inhibitor with both bone-forming and antiresorptive effects, first appeared in 2021 and became common from 2023, tracking its regulatory approval in mainland China in May 2026. More troubling, of 17 guidelines recommending denosumab, only three addressed the critical need for follow-on antiresorptive therapy after discontinuation, despite international evidence that stopping the drug triggers rebound bone turnover, rapid bone loss, and increased vertebral fracture risk.

Two systemic gaps separated Chinese guidance from its international counterparts. Fracture liaison services, coordinated multidisciplinary programmes that identify patients after a first fracture and initiate treatment to prevent the next one, were recommended in only nine guidelines, or 28 percent, even though such services demonstrably reduce re-fracture risk, mortality, and costs, and are standard recommendations in the US and UK. Health economic evaluation fared even worse: only two guidelines considered cost-effectiveness at all, despite Chinese analyses suggesting that zoledronate becomes cost-effective at a 10-year fracture probability above 7 percent and that drug-specific thresholds could rationally guide treatment initiation. In a country where fewer than one DXA machine exists per million people, the review also noted promising alternatives, including opportunistic quantification of bone density from CT scans already performed for other reasons, an approach shown to be feasible in a nationwide study of nearly 70,000 Chinese adults and cost-effective compared with DXA.

The AGREE II appraisal exposed deeper methodological weaknesses. Guidelines scored well on scope and purpose, with a mean of 87.8 percent, and on clarity of presentation at 77.8 percent, but collapsed on rigour of development, which averaged just 42.1 percent, and on applicability, the lowest domain at 29.0 percent. Only 14 of the 32 guidelines described systematic methods for searching evidence and formulating recommendations, only seven incorporated patient or consumer input, and merely two provided clear statements of independence from funding or sponsorship. Nineteen guidelines graded their evidence, but most offered little detail on how those grades were assigned, making it difficult to compare the strength of one recommendation against another.

The review also flagged a striking gender blind spot. Only one guideline focused specifically on osteoporosis in men, even though men suffer higher mortality after osteoporotic fractures than women and are more frequently underdiagnosed and undertreated. The evidence base itself is skewed: 64 percent of registered osteoporosis trials include only women, and even in mixed-sex trials women dominate enrolment, leaving treatment efficacy in men often inferred from surrogate bone density measures rather than actual fracture outcomes.

The authors conclude that China needs a more coherent national guideline built on systematic evidence grading, locally generated research, robust economic evaluation, and widespread implementation of fracture liaison services. With fracture costs heading toward 25 billion dollars annually and half the world’s hip fractures soon expected in Asia, the country’s fractured guideline landscape, ironically mirroring the disease it treats, may prove as consequential as any single clinical recommendation it contains.

Subject of Research: Consistency and quality of clinical practice guidelines for osteoporosis management in China

Article Title: Clinical guidelines for the management of osteoporosis in China: a systematic review

Article References: Wei, T., Xu, L., Xiong, S., Zhang, X., Tian, M., Yang, M., Wang, Y., Chen, M., Abbott, P., Wong, P. K. K., Kolt, G. S., & Si, L. (2026). Clinical guidelines for the management of osteoporosis in China: a systematic review. Frontiers in Endocrinology, 17, Article 1943964. https://doi.org/10.3389/fendo.2026.1943964

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1943964

Keywords: osteoporosis, clinical guidelines, China, systematic review, AGREE II, fracture liaison services, DXA, bisphosphonates, denosumab, health economics, ageing population, traditional Chinese medicine

The numbers deserve close scrutiny because they quantify a treatment gap that has persisted for decades despite abundant evidence. Hip fractures in particular carry a grim prognosis: they are associated with substantial morbidity and an estimated one-year mortality approaching 20 percent, a figure that places them in the same category of lethality as many cancers. Antifracture medications, including bisphosphonates, anabolic agents, RANK ligand inhibitors, and selective estrogen receptor modulators, have repeatedly been shown to reduce the risk of subsequent fractures and, in some studies, to lower mortality itself. In cardiology, no physician would discharge a patient after a heart attack without aspirin, a statin, and a beta blocker; secondary prevention after myocardial infarction is considered non-negotiable. The burden of disease imposed by a hip fracture is comparable to that of a heart attack, yet the parallel discipline of secondary prevention after fracture has simply never taken hold in routine practice.

The study at the center of this conversation, conducted by Silverstein and colleagues, is a retrospective cohort analysis that linked electronic health records to pharmacy prescription fill data across a single large academic health system. The researchers identified patients older than 50 years admitted between January 1, 2017, and August 31, 2023, for a hip, femur, pelvis, or vertebral fracture that was non-traumatic in origin. The primary outcome was receipt of any antifracture medication, whether initiated in the emergency department, during the inpatient stay, or in the outpatient setting within 180 days of discharge. What makes the analysis more than another grim audit is its attention to continuity: it asked whether a medication started in the hospital actually survived the transition to outpatient care, a question that has rarely been answered with linked fill data at this level of detail.

The results contain both a scandal and a surprise. The scandal is the 6 percent treatment rate among patients who had never previously received therapy, a figure that underscores how little progress has been made despite years of consensus recommendations calling for secondary fracture prevention in every eligible patient. The surprise is what happened among the small treated minority: 77 percent of those who did receive an antifracture medication got it during the hospital encounter itself, and, crucially, 71 percent of patients who started a medication in the hospital remained on therapy after discharge. In other words, the hospital is not a dead end for osteoporosis care. When treatment begins at the bedside, it tends to stick. Bisphosphonates dominated the prescribing pattern, accounting for 92 percent of medications, and hip fracture was the most common diagnosis, representing 60 percent of hospitalized patients.

Equally revealing are the disparities that emerged. Men, Black patients, those with longer hospital stays, and those with femur fractures were less likely to receive an antifracture medication, a pattern that echoes documented inequities in secondary fracture treatment by age, race, and sex. Patients discharged to skilled nursing facilities were also less likely to be treated, even though evidence demonstrates that frail older adults, the very population most concentrated in such facilities, still derive meaningful benefit from osteoporosis medications. These gradients suggest that the treatment gap is not randomly distributed but follows the fault lines of the health care system itself, with the most vulnerable patients, those navigating complex post-acute transitions, falling through the widest cracks.

The study has limitations that its commentators, geriatricians Annie Yang, William Hung, and Katherine Ritchey, are careful to note. It examined a single academic health system, so national generalization requires larger, nationally representative cohorts. Outpatient follow-up was truncated at 180 days after discharge, meaning that treatments initiated later would have been missed and the true treatment rate may be somewhat higher. Still, the direction of the findings is unlikely to be an artifact; the undertreatment of osteoporosis after fracture has been replicated across countries, databases, and decades, and the new analysis reinforces rather than revises that consensus.

What distinguishes the editorial response is its practicality. The authors argue that the 71 percent persistence rate among hospital-initiated patients should act as a catalyst: if starting the medication in the hospital works, then emergency physicians and hospitalists should be equipped and expected to start it. Some measures require nothing more than better communication. Discharge summaries should list osteoporosis as an active diagnosis or include explicit follow-up items, such as a prompt for the primary care physician or nursing home to review the antifracture medication started inpatient. Transitions of care are moments of vulnerability, but they are also moments of leverage, when a clearly documented plan can carry an evidence-based intervention across institutional boundaries that so often swallow it.

System-level tools already exist and have demonstrated their value. Clinical decision support embedded in the electronic health record can prompt clinicians to initiate antifracture therapy at the moment of admission, and a population-based before-after analysis found that simply introducing an order set after hip fracture improved both initiation and persistence of osteoporosis medications. Fracture Liaison Services, in which a coordinator systematically identifies fracture patients and shepherds them through assessment and treatment, and the American Orthopaedic Association’s Own the Bone program have both been shown to increase prescribing after incident fractures. The problem is dissemination: these programs remain patchy, available to a minority of fracture patients nationwide. The editorial points to the Centers for Medicare & Medicaid Services Age-Friendly Hospital measure, under which hospitals must now attest to delivering age-friendly care across domains including medication management and frailty screening, as a potential regulatory lever. If post-fracture care were explicitly integrated into one of those domains, hospitals would have a structural reason to invest in secondary fracture prevention.

History suggests, however, that the most powerful engine of change in American hospitals is financial. When CMS began measuring and publicly reporting hospital quality for heart failure and heart attacks in the early 2000s, institutions poured resources into cardiovascular care, and outcomes such as readmissions and mortality are now tied to reimbursement through programs like the Hospital Readmissions Reduction Program. The editorial’s implicit argument is that fracture-related outcomes deserve the same treatment: measure them, report them publicly, and attach them to payment, and hospitals will find the organizational will to close a gap that voluntary exhortation has failed to close for a generation. Cardiology offers the template; osteoporosis needs only the mandate.

The deeper conceptual shift the editorial demands is deceptively simple. Osteoporosis treatment has long been framed as an outpatient problem, the province of primary care physicians and DXA scans ordered months after the fact, if at all. The new evidence inverts that framing. The hospital admission for a fragility fracture is the single moment when the patient, the diagnosis, and the indication for treatment converge in one place, under the care of clinicians with the prescription in hand. Treating the hospital as part of osteoporosis care rather than a departure from it would not require new drugs or new science, only the application of practices already proven to work. For the 94 percent of treatment-naive fracture patients currently leaving without therapy, that reframing cannot come soon enough.

Subject of Research: Underprescribing of antifracture medications after non-traumatic fracture and the role of hospitals in secondary fracture prevention

Article Title: Hospitals Are an Opportunity to Close the Osteoporosis Treatment Gap

Article References: Yang, A. W., Hung, W. W., & Ritchey, K. (2026). Hospitals Are an Opportunity to Close the Osteoporosis Treatment Gap. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10880-y

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10880-y

Keywords: osteoporosis, hip fracture, secondary fracture prevention, antifracture medications, bisphosphonates, hospital care, Fracture Liaison Services, clinical decision support, health disparities, CMS quality measures, geriatrics, Journal of General Internal Medicine

The scale of the problem is staggering. In 2019 alone, an estimated 4.3 million new fragility fractures occurred across the EU27, Switzerland, and the United Kingdom, including approximately 827,000 hip fractures. The direct cost of these new fractures reached 36.3 billion euros, with an additional 19.0 billion euros attributable to long-term disability from fractures sustained in previous years. When pharmacological assessment and treatment costs of 1.6 billion euros are added, the total direct cost climbed to 56.9 billion euros in a single year. Healthcare costs remain elevated above pre-fracture levels for five full years after the injury, placing an unsustainable strain on health systems already stretched by aging populations.

What makes these figures particularly troubling is how preventable many of these fractures are. More than 95 percent of hip fractures are caused by falling, yet the clinical systems designed to prevent falls and those designed to prevent fractures operate almost entirely in isolation from one another. Hip fracture outcomes are grim: one-year mortality reaches 20 to 24 percent, and among survivors, 40 percent are unable to walk independently while 60 percent still require assistance a full year after injury. Approximately one-third of patients become fully dependent or require residential care within twelve months of sustaining a hip fracture.

The biological logic for integration is compelling. The paper presents a conceptual framework showing how bone fragility and fall risk jointly determine fracture probability, with their relative contributions shifting over time. A common geriatric syndrome called osteosarcopenia—the combination of sarcopenia and osteopenia or osteoporosis—illustrates this overlap, affecting an estimated 5 to 37 percent of community-dwelling older adults and elevating the risk of both falls and fractures simultaneously. Crucially, researchers have documented an imminent subsequent fracture risk after both an incident fracture and an incident fall, and conversely, an increased risk of falling soon after a fracture. This bidirectional cascade means that missing one risk dimension inevitably undermines the other.

Despite this, clinical practice lags badly. In a recent survey among European healthcare professionals, fewer than 60 percent of respondents reported including fracture risk assessment often or always within the multifactorial fall risk assessment. On the fracture side, fall risk assessment is not routinely performed in many Fracture Liaison Services, the specialized secondary prevention programs established after a first fracture. In a 2025 national UK evaluation, only about 65 percent of FLS patients received or were referred for a fall risk assessment, with substantial variation between services, and the picture is likely worse or entirely absent in many other countries. The authors contend that FLS programs are uniquely positioned to operationalize integrated care but frequently remain predominantly bone-focused rather than comprehensively risk-focused.

The paper lays out a detailed technical roadmap for how fracture risk assessment can be embedded within fall prevention services, drawing on the 2022 World Guidelines for Fall Prevention and Management. These guidelines introduce a fall risk stratification algorithm for community-dwelling older adults and recommend that those at moderate to high risk of falls undergo bone health assessment using validated tools. Fracture risk calculators such as FRAX, Garvan, and QFracture can identify older adults at high fracture risk, with Garvan and QFracture already incorporating falls as a predictor. FRAXplus further refines conventional FRAX estimates by accounting for the number of falls in the previous year, allowing clinicians to treat fall history as a modifiable fracture risk amplifier that directly informs both risk stratification and therapeutic choice.

Conversely, established osteoporosis management pathways should embed fall prevention. An internationally applicable algorithm for postmenopausal women categorizes fracture risk into low, intermediate, and very high zones using FRAX, with bone densitometry and recalculation refining intermediate cases. Women with a prior fragility fracture are automatically considered at least high risk. The authors emphasize that fall prevention strategies must be embedded within treatment pathways for patients at high and very high fracture risk, and that cognitively impaired and dementia patients should never be denied fracture prevention measures, including pharmacological osteoporosis treatments. This population deserves particular attention: 60 to 80 percent of people with dementia fall annually, and cognitive impairment is present in approximately 40 percent of all older adults with hip fractures.

Education represents another critical pillar. Among nearly 4,000 European healthcare professionals surveyed, approximately 12 percent reported low or very low knowledge of both falls and bone health, and 35.9 percent reported low knowledge of orthogeriatric care. Only about a quarter of surveyed professionals agreed that their undergraduate education adequately prepared them for fall prevention in clinical practice. The authors call for interprofessional training that bridges medicine, physiotherapy, nursing, pharmacy, and dietetics, alongside a core set of competencies for integrated fall and fracture assessment that local teams can adapt to their resources while remaining evidence-based.

On the policy front, the paper argues that integrated fall and fracture prevention must be recognized as a public health priority and incorporated into national healthy aging strategies aligned with the WHO’s Decade of Healthy Ageing. Promising national initiatives already exist: France launched a 2022 plan targeting a 20 percent reduction in fall-related fractures and deaths; the Netherlands has introduced an Integrated Approach to Fall Prevention strategy; and Belgium operates a dedicated Center of Expertise for Falls and Fracture Prevention in Flanders. Hip fracture registries, another policy instrument, should include fall prevention quality markers, as the Danish National Hip Fracture Database has done since 2010.

Emerging technologies offer powerful new tools. Wearable sensors capturing real-world balance and mobility data, combined with AI-driven predictive models, demonstrate superior fall prediction performance compared with traditional approaches, while in silico clinical trials enable simulation of virtual populations to optimize preventive interventions before deployment. Emerging pharmacological findings add intrigue: pooled analyses suggest that romosozumab and denosumab may each reduce fall risk in postmenopausal women with osteoporosis, hinting at mechanisms that might involve muscle mass, though the authors caution that studies with falls as the primary outcome are still needed. The WHO and ESCEO have signed a five-year collaboration agreement to develop a strategic global roadmap on bone health and aging, signaling that momentum toward truly integrated prevention may finally be building. The authors’ message is unambiguous: unify the science, unify the services, and millions of preventable fractures and falls could be avoided.

Subject of Research: Integrated fall and fragility fracture prevention in older adults through coordinated international clinical, educational, policy, and research strategies

Article Title: Position paper: a coordinated approach to fracture and fall prevention from seven international organizations

Article References: van der Velde, N., Seppala, L. J., Bahat, G., Blain, H., Casas Herrero, A., Harvey, N. C., Masud, T., Rizzoli, R., Reginster, J.-Y., Ruggiero, C., Barbagallo, M., de Lima, A. B., Bonnici, M., Bousquet, J., Cortet, B., Chiari, L., Dionyssiotis, Y., Dreinhöfer, K., Duque, G., … Öztürk, Y. (2026). Position paper: a coordinated approach to fracture and fall prevention from seven international organizations. European Geriatric Medicine. https://doi.org/10.1007/s41999-026-01596-7

Image Credits: AI Generated

DOI: 10.1007/s41999-026-01596-7

Keywords: fall prevention, fragility fractures, osteoporosis, geriatric medicine, Fracture Liaison Services, hip fracture, osteosarcopenia, integrated care, healthy aging, bone health, wearable sensors, public health policy